ID24358A - Pengobatan atau propilaksis dari kanker prostatik dan hiperplasia prostatik benign dengan modulator selektif reseptor estrogen - Google Patents

Pengobatan atau propilaksis dari kanker prostatik dan hiperplasia prostatik benign dengan modulator selektif reseptor estrogen

Info

Publication number
ID24358A
ID24358A IDW991188A ID991188A ID24358A ID 24358 A ID24358 A ID 24358A ID W991188 A IDW991188 A ID W991188A ID 991188 A ID991188 A ID 991188A ID 24358 A ID24358 A ID 24358A
Authority
ID
Indonesia
Prior art keywords
prostatic
propilactic
benost
treatment
selective modulators
Prior art date
Application number
IDW991188A
Other languages
English (en)
Inventor
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ID24358A publication Critical patent/ID24358A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IDW991188A 1997-04-09 1998-04-07 Pengobatan atau propilaksis dari kanker prostatik dan hiperplasia prostatik benign dengan modulator selektif reseptor estrogen ID24358A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4322397P 1997-04-09 1997-04-09

Publications (1)

Publication Number Publication Date
ID24358A true ID24358A (id) 2000-07-13

Family

ID=21926126

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991188A ID24358A (id) 1997-04-09 1998-04-07 Pengobatan atau propilaksis dari kanker prostatik dan hiperplasia prostatik benign dengan modulator selektif reseptor estrogen

Country Status (16)

Country Link
EP (1) EP0975629A4 (id)
JP (1) JP2001518900A (id)
KR (1) KR20010006218A (id)
CN (1) CN1259944A (id)
AU (1) AU6966198A (id)
BR (1) BR9808515A (id)
CA (1) CA2286204A1 (id)
EA (1) EA199900914A1 (id)
HU (1) HUP0003589A3 (id)
ID (1) ID24358A (id)
IL (1) IL132277A0 (id)
NO (1) NO994903L (id)
PL (1) PL336205A1 (id)
TR (1) TR199902701T2 (id)
WO (1) WO1998045288A1 (id)
ZA (1) ZA982819B (id)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
WO2002089801A1 (en) * 2001-05-10 2002-11-14 Cedars Sinai Medical Center Use of benzothiophenes to treat and prevent prostave cancer
RU2261716C1 (ru) * 2004-02-24 2005-10-10 Долженков Сергей Дмитриевич Способ профилактики гнойно-воспалительных осложнений у больных доброкачественной гиперплазией простаты в послеоперационном периоде
JP5123935B2 (ja) * 2006-05-22 2013-01-23 ホルモス メディカル リミテッド 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
NZ710385A (en) 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429922A (en) * 1988-03-09 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for distinguishing virulent and non-virulent toxoplasma infections
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
HUP0003589A2 (hu) 2002-01-28
NO994903D0 (no) 1999-10-08
EP0975629A4 (en) 2001-03-21
IL132277A0 (en) 2001-03-19
KR20010006218A (ko) 2001-01-26
WO1998045288A1 (en) 1998-10-15
TR199902701T2 (xx) 2000-02-21
EP0975629A1 (en) 2000-02-02
ZA982819B (en) 1999-10-04
BR9808515A (pt) 2001-06-19
EA199900914A1 (ru) 2000-04-24
JP2001518900A (ja) 2001-10-16
HUP0003589A3 (en) 2002-02-28
CA2286204A1 (en) 1998-10-15
CN1259944A (zh) 2000-07-12
AU6966198A (en) 1998-10-30
PL336205A1 (en) 2000-06-05
NO994903L (no) 1999-12-09

Similar Documents

Publication Publication Date Title
ID28114A (id) Sitokin mamalia; interleukin-b30 dan pereaksi-pereaksi terkait
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
DK0968208T3 (da) Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia
DE69927084D1 (de) Sigma-delta Modulator und Modulationsverfahren
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
ID27986A (id) Pengobatan terhadap gangguan sistem syaraf pusat dengan modulator reseptor estrogen selektif
EP0989857A4 (en) NEW THERAPEUTIC ACTIVE SUBSTANCES THAT INTERRUPT IN ENZYMATIC PROCESSES
DE69832657D1 (de) Empfangseinrichtungen und Empfangsverfahren
EE9900415A (et) IQ-modulaator ja sellega seotud meetod
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
DE69714261D1 (de) Verbesserte mischdüse
AU5881998A (en) Modulator and modulation method
ID23159A (id) Wafer dan pembuatannya
NO20011162L (no) Fremgangsmåter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
ID24828A (id) Komposisi-komposisi farmasi dari tizoksianida dan nitazoksanida
DE69830435D1 (de) Räumlischer LichtModulator und Anzeige
IL132277A0 (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators
DE69802158D1 (de) Doppelgegentaktmodulator und vier Phasen Modulationseinrichtung
ID26873A (id) Kombinasi terapeutik yang terdiri dari modulator reseptor estrogen selektif dan hormon paratiroid
ID23653A (id) Pencegahan kanker payudara dengan modulator reseptor estrogen selektif
DE69831626D1 (de) Datenmodulation und -übertragung
ID22345A (id) Penghilangan 6-aminokapronitril dari campuran-campuran yang terdiri dari 6-aminokapronitril dan suatu imina
DE69836559D1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis